Adenocarcinoma of lung (disorder)
|
0.500 |
Biomarker
|
disease |
BEFREE |
Neuropeptide gastrin-releasing peptide induces PI3K/reactive oxygen species-dependent migration in lung adenocarcinoma cells.
|
28351312 |
2017 |
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The PIK3CA mutation rate in lung adenocarcinoma with acquired resistance to EGFR TKI is not higher than that in EGFR TKI-naïve tissue specimens (2.9% (6/207) vs. 1.8%; p = 0.344).
|
27734950 |
2016 |
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
Adenocarcinoma of lung (disorder)
|
0.500 |
Biomarker
|
disease |
BEFREE |
<i>PTEN</i> Inhibits Cell Proliferation, Promotes Cell Apoptosis, and Induces Cell Cycle Arrest via Downregulating the PI3K/AKT/<i>hTERT</i> Pathway in Lung Adenocarcinoma A549 Cells.
|
27822469 |
2016 |
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A PIK3CA mutation was detected in 7 of 115 cases of metastatic ADC (6.1%).
|
27007084 |
2016 |
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We explored the status of PIK3CA mutation and evaluated its genetic variability, treatment, and prognosis in patients with lung adenocarcinoma.
|
27554588 |
2016 |
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Two STAT3 siRNAs decreased PD-L1 expression by 10-32% in two of the three KRAS-mutant lung adenocarcinoma cell lines (p < 0.05), while the PI3K inhibitor LY294002 (40 μM) did not change the expression level.
|
27846317 |
2016 |
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
MET exon 14 skipping mutation predicts for response to MET TKIs in human lung adenocarcinomas but co-occurrence of PIK3CA mutation needs to be better evaluated as a modifier of response to TKI therapy.
|
26791794 |
2015 |
Adenocarcinoma of lung (disorder)
|
0.500 |
Biomarker
|
disease |
BEFREE |
To elucidate how EGFR signaling is linked to metabolic activity, we investigated the involvement of the RAS/MEK/ERK and PI3K/AKT/mammalian target of rapamycin (mTOR) pathways on metabolic alteration in lung adenocarcinoma (LAD) cell lines with activating EGFR mutations.
|
26023239 |
2015 |
Adenocarcinoma of lung (disorder)
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas.
|
25596284 |
2015 |
Adenocarcinoma of lung (disorder)
|
0.500 |
Biomarker
|
disease |
BEFREE |
We investigated the mutation profile of an updated driver events list on receptor tyrosine kinase/RAS/PI3K axis and the clinicopathologic implications in a cohort of never-smoker predominated Chinese lung adenocarcinoma.
|
26098749 |
2015 |
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A concurrent PIK3CA mutation is a poor prognostic factor in patients with advanced EGFR-mutant or KRAS-mutant lung adenocarcinomas.
|
26334752 |
2015 |
Adenocarcinoma of lung (disorder)
|
0.500 |
Biomarker
|
disease |
BEFREE |
This study reveals a critical role for the PTEN/PI3K pathway in both SCLC and lung adenocarcinoma and provides an ideal system to test the phosphoinositide 3-kinase (PI3K) pathway inhibitors as targeted therapy for subsets of patients with SCLC.
|
24482365 |
2014 |
Adenocarcinoma of lung (disorder)
|
0.500 |
Biomarker
|
disease |
BEFREE |
These data identify RIT1 as a driver oncogene in a specific subset of lung adenocarcinomas and suggest PI3K and MEK inhibition as a potential therapeutic strategy in RIT1-mutated tumors.
|
24469055 |
2014 |
Adenocarcinoma of lung (disorder)
|
0.500 |
Biomarker
|
disease |
BEFREE |
Here, we have shown that phosphatidylinositol 3-kinase-targeted (PI3K-targeted) therapy suppresses metastasis in a mouse model of Kras/Tp53-mutant lung adenocarcinoma that develops metastatic disease due to high expression of ZEB1.
|
24762440 |
2014 |
Adenocarcinoma of lung (disorder)
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
However, iMDK did not reduce the cell viability of MDK-negative A549 lung adenocarcinoma cells or normal human lung fibroblast (NHLF) cells indicating its specificity. iMDK suppressed the endogenous expression of MDK but not that of other growth factors such as PTN or VEGF. iMDK suppressed the growth of H441 cells by inhibiting the PI3K pathway and inducing apoptosis.
|
23976985 |
2013 |
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In this series, 230 resected lung adenocarcinomas from smoker (>100 cigarettes in lifetime) at single center (Shanghai Cancer Center, Shanghai, China) were tested for mutation in EGFR, KRAS, BRAF, HER2, EML4-ALK and PIK3CA.
|
23098378 |
2013 |
Adenocarcinoma of lung (disorder)
|
0.500 |
Biomarker
|
disease |
BEFREE |
20(S)-protopanaxadiol triggers mitochondrial-mediated apoptosis in human lung adenocarcinoma A549 cells via inhibiting the PI3K/Akt signaling pathway.
|
24117074 |
2013 |
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Finally, in nude mice bearing established HCT15 and H1975 subcutaneous tumor xenografts, the combined treatment with pimasertib and BEZ235 (a dual PI3K/mTOR inhibitor) or with sorafenib caused significant tumor growth delays and increase in mice survival as compared to single agent treatment.
|
23629727 |
2013 |
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
104 consecutively resected lung adenocarcinomas from 396 non-smoker females (less than 100 cigarettes in a lifetime) at a single institution (Tongji University, Shanghai, China) were analyzed for mutations in EGFR, EML4-ALK, KRAS, HER2, BRAF, and PIK3CA.
|
22707299 |
2012 |
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras(G12D-LSL) mice.
|
22684718 |
2012 |
Adenocarcinoma of lung (disorder)
|
0.500 |
Biomarker
|
disease |
BEFREE |
We examined epidermal growth factor receptor (EGFR), Kirsten rate sarcoma viral oncogene homolog (KRAS), v-Raf murine sarcoma viral oncogene homolog B1 (BRAF), human epidermal growth factor receptor 2 (HER2), PIK3CA, v-akt murine thymoma vial oncogene homolog 1 (AKT1), v-ras neuroblastoma viral oncogene homolog (NRAS), dual specificity mitogen-activated protein kinase kinase 1 (MEK1), and anaplastic lymphoma kinase (ALK) in patients with adenocarcinoma of the lung to identify driver mutations.
|
22135231 |
2012 |
Adenocarcinoma of lung (disorder)
|
0.500 |
Biomarker
|
disease |
CTD_human |
We examined epidermal growth factor receptor (EGFR), Kirsten rate sarcoma viral oncogene homolog (KRAS), v-Raf murine sarcoma viral oncogene homolog B1 (BRAF), human epidermal growth factor receptor 2 (HER2), PIK3CA, v-akt murine thymoma vial oncogene homolog 1 (AKT1), v-ras neuroblastoma viral oncogene homolog (NRAS), dual specificity mitogen-activated protein kinase kinase 1 (MEK1), and anaplastic lymphoma kinase (ALK) in patients with adenocarcinoma of the lung to identify driver mutations.
|
22135231 |
2012 |
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In this surgical series, 52 resected lung adenocarcinomas from never-smokers (< 100 cigarettes in a lifetime) at a single institution (Fudan University, Shanghai, China) were analyzed concurrently for mutations in EGFR, KRAS, NRAS, HRAS, HER2, BRAF, ALK, PIK3CA, TP53 and LKB1.
|
20855837 |
2010 |